Galectin Therapeutics Announces Addition to Russell Microcap Index
NEWTON, Mass.--(BUSINESS WIRE)--Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has been added to the Russell Microcap Index effective at the close of equity markets on June 22, 2012.